WIPO – 检索国际和国家专利汇编

1.WO/2022/175436INFLUENZA VIRUS DEFECTIVE INTERFERING PARTICLES FOR USE IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF CORONAVIRIDAE INFECTION

WO - 25.08.2022

国际分类 A61P 31/14 申请号 PCT/EP2022/054047 申请人 MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. 发明人 KUPKE, Sascha

The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.

2.WO/2021/216467A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES

WO - 28.10.2021

国际分类 A61K 31/7088 申请号 PCT/US2021/028004 申请人 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 发明人 NEL, Andre, E.

In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against one or more viral proteins and/or protein fragments. In certain embodiments the immunogenic nanoparticles raise an immune response directed against a virus (e.g., SARS-CoV-2 (2019-nCoV), SARS-CoV-2, and MERS-CoV, and the like). In certain embodiments the immunogenic nanoparticles comprise a nanoparticle formed from one or more biocompatible polymer(s), one or more viral proteins or fragments thereof encapsulated within or attached to the biocompatible polymer(s) where the viral protein or fragment thereof comprises an antigen to which an immune response is to be induced by administration of the immunogenic nanoparticle to a mammal and where the immunogenic nanoparticle further comprises an adjuvant (e.g., a STING agonist).

3.20150275183Human Betacoronavirus lineage C and identification of N-terminal dipeptidyl peptidase as its virus receptor

US - 01.10.2015

国际分类 C12N 7/00 申请号 14430010 申请人 Erasmus University Medical Center Rotterdam 发明人 Bartholomeus Leonardus Haagmans

The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.

4.3156263AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LIQUID FORM (VARIANTS)

CA - 09.08.2022

国际分类 A61K 39/12 申请号 3156263 申请人 FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION 发明人 ZUBKOVA, OLGA VADIMOVNA

The invention relates to biotechnology, immunology and virology. The claimed agent can be used for the prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2.The technical aim of the claimed group of inventions is to create agents containing a single active component and along with this ensuring the effective induction of immune response to the SARS-CoV-2 virus among broad strata of the population.Solution of the technical problem is a variant of the agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in liquid form which contains, as a single active component, the expression vector based on the genome of the recombinant strain of human adenovirus serotype 26, wherein the El and E3 regions are deleted and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3.Also, there is created a variant of the agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in liquid form which contains, as a single active component, the expression vector based on the genome of the recombinant strain of human adenovirus serotype 5, wherein the El and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3.Further, there is claimed a variant of the agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in liquid form which contains, as a single active component, the expression vector based on the genome of the recombinant strain of simian adenovirus serotype 25, wherein the El and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3.At that, for the particular case of implementation, a buffer solution of the agent for liquid form contains the following, mass%:tris from 0,1831 to 0,3432sodium chloride from 0,3313 to 0,6212sucrose from 3,7821 to 7,0915magnesium chloride hexahydrate from 0,0154 to 0,0289EDTA from 0,0029 to 0,0054polysorbate-80 from 0,0378 to 0,0709ethanol 95% from 0,0004 to 0,0007water the remaining part.Each of the agent variants is used for inducing specific immunity against the severe acute respiratory syndrome SARS-CoV-2 virus.With that, the agent is intended for intranasal or intramuscular administration. Also, the agent can be administered concomitantly and simultaneously via intranasal and intramuscular routes.

5.WO/2004/092360THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS

WO - 28.10.2004

国际分类 A61K 35/76 申请号 PCT/US2004/011710 申请人 CHIRON CORPORATION 发明人 RAPPUOLI, Rino

An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.

6.WO/2022/135683USE OF A BIRNAVIRUS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF A DISEASE CAUSED BY A NIDOVIRUS

WO - 30.06.2022

国际分类 C12N 7/00 申请号 PCT/EP2020/087550 申请人 PROBIOGEN AG 发明人 KOVESDI, Imre

The present invention relates to a birnavirus for use in the treatment of a disease caused by a nidovirus. Further, the present invention relates to a combination comprising at least one birnavirus and at least one further active agent for use in the treatment of a disease caused by a nidovirus. Furthermore, the present invention relates to a pharmaceutical composition comprising the birnavirus or the combination for use in the treatment of a disease caused by a nidovirus.

7.3156456THE USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 FOR REVACCINATION OF POPULATION (VARIANTS)

CA - 27.07.2022

国际分类 A61K 39/12 申请号 3156456 申请人 FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION 发明人 ZUBKOVA, OLGA VADIMOVNA

The group of inventions relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with El and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. In addition an agent is used, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with El and E3 sites deleted from the genome, and the site 0RF6-Ad26 is substituted for 0RF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, or containing only component 2. Furthermore, an agent is used, such agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with El and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. The group of invention enables to create safe and efficacious agents providing extension of postvaccinal immunity against virus SARS-CV-2, and is intended for revaccination of population against the diseases caused by severe acute respiratory syndrome virus SARS-CoV-2.

8.3156252AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LYOPHILIZED FORM (VARIANTS)

CA - 25.07.2022

国际分类 A61K 39/215 申请号 3156252 申请人 FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION 发明人 ZUBKOVA, OLGA VADIMOVNA

9.WO/2021/178416IMMUNE-MEDIATED CORONAVIRUS TREATMENTS

WO - 10.09.2021

国际分类 A61K 35/76 申请号 PCT/US2021/020490 申请人 HEAT BIOLOGICS, INC. 发明人 HUTCHINS, Jeff T.

The present invention provides an expression vector, host cells, methods and kits for the treatment or prevention of a coronavirus infection in a subject.

10.3156448THE USE OF THE AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN SUBJECTS ABOVE 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS)

CA - 21.08.2022

国际分类 A61K 39/12 申请号 3156448 申请人 FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION 发明人 ZUBKOVA, OLGA VADIMOVNA

The invention relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with El and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. In addition the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with El and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, or containing only component 2 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. Furthermore, the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with El and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. The inventions provide effective induction of the immune response against SARS-CoV-2 virus in subjects above 60 years of age and also having chronic diseases.

1 / 60

转到检索输入栏	`CTRL` + `SHIFT` +
转到结果（选定结果）	`CTRL` + `SHIFT` +
转到详细信息（选定标签）	`CTRL` + `SHIFT` +
转到下一页	`CTRL` +
转到上一页	`CTRL` +

转到下一个结果/图像	/
转到上一个结果/图像	/
向上滚动	`Page Up`
向下滚动	`Page Down`
滚动至顶部	`CTRL` + `Home`
滚动至底部	`CTRL` + `End`

正在处理

进入国家阶段

规范文件

设置

反馈

查看申请

保存查询

查询树

优化选项

完整查询

并排视图快捷键

分析

转到下一个标签
转到上一个标签